The BCG report said that India has already emerged as a highly attractive destination for drug development and manufacturing as it offers pharmaceutical services priced around 20 per cent lower ...

Sun Pharma, India's largest pharmaceutical company, is set to acquire Checkpoint Therapeutics for $355 million. This strategic acquisition will enhance Sun Pharma's specialty portfolio ...

But much will depend on how quickly and effectively the funds are deployed, if regulatory bottlenecks are eased, and how actively private players participate. India is making a push to move beyond ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

India's Sun Pharmaceutical Industries said on Monday it will acquire Checkpoint Therapeutics , a U.S.-based immunotherapy and targeted oncology company, for $355 million.

Mankind Pharma, India’s fourth largest drugmaker by domestic sales, is setting its sights on anti-obesity drugs like Semaglutide, better known by brand names Ozempic and Wegovy, which goes off ...

India's pharma giant Sun Pharma is to acquire Checkpoint Therapeutics (NASDAQ:CKPT)—an immunotherapy and targeted oncology company—for an upfront cash payment o ...

India continues to play a crucial role in the US generic drug supply chain, supplying key starting materials (KSMs), active pharmaceutical ingredients (APIs), and finished formulations.

Eli Lilly and Co. has begun selling its blockbuster weight-loss and diabetes drug Mounjaro in India, pipping rivals in a ...

India must transition from being a manufacturing hub in pharma sector to becoming a global leader in innovation, said former NitiAayog CEO Amitabh Kant in his keynote address at BioAsia 2025 on ...

Mankind Pharma has launched its affordable generic version empagliflozin in India for diabetes following its patent expiration. The launch follows patent expiration of empagliflozin sold by German ...

Its time for Indian pharma companies to look beyond the U.S. market as the Trump administration has threatened to impose 25% tariff on pharmaceutical imports. This move would disrupt India’s ...